Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

Thursday, October 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals will announce its third quarter financial results for 2026 on October 29, 2026. The company will hold a conference call at 8:30 am ET to discuss these results and future expectations. This event highlights Alnylam's commitment to transparency and investor communication.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alnylam is a leading company in RNAi therapeutics.
  • The upcoming conference call will provide insights into future expectations.
  • The company is actively engaging with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
ALN-4324
Phase 2 · Type 2 Diabetes Mellitus (T2DM)

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2026 on Thursday, October 29, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2026 results as well as expectations for the future via conference call on Thursday, October 29, 2026 at 8:30 am ET. A live audio w

Frequently Asked Questions

When will Alnylam report its Q3 2026 financial results?

Alnylam will report its Q3 2026 financial results on October 29, 2026.

What time is the Alnylam conference call?

The conference call will take place at 8:30 am ET on October 29, 2026.

What will be discussed in the conference call?

The call will cover the financial results and future expectations of Alnylam.

Where is Alnylam Pharmaceuticals located?

Alnylam Pharmaceuticals is based in Cambridge, Massachusetts.

ShareAdd on Google
Tags: ALNY Alnylam Pharmaceuticals RNAi therapeutics financial results conference call Q3 2026
Last updated: Oct 15, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 2
Type 2 Diabetes Mellitus (T2DM) →

Catalyst track record

+36%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →